Pediatric B-cell lymphoma treatment study using established care
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child was diagnosed between birth and age 18.
- The lymphoma type is one of these: Burkitt’s lymphoma, diffuse large B-cell lymphoma, primary mediastinal lymphoma, primary CNS lymphoma, or B-cell (Burkitt) AL.
- A parent or legal guardian can sign consent for the treatment.
- Your child has not had a prior cancer (no previous malignancy).
- Your child has not had an organ transplant.
- Your child does not have HIV/AIDS or a serious immune system weakening condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests two new treatment combinations for children and young adults with B-cell non-Hodgkin lymphoma that has come back or not responded to previous therapy. The goal is to find better options for treating this cancer.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This trial looks at a treatment approach for children and adolescents with classical Hodgkin lymphoma. It may help by testing how well the treatment controls the cancer and is tolerable in young patients.
Hear when a new Burkitt Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.